Inhibitor Therapeutics, Inc. Overview
Pro stress-test →Inhibitor Therapeutics is a publicly traded, clinical stage pharmaceutical development company. The company is focused on developing and commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders. Its lead product candidate, SUBA-Itraconazole, is a patented, oral formulation of the currently FDA approved and marketed, well-understood, anti-fungal drug, itraconazole, which, when studied to treat patients with cancer, has demonstrated activity against multiple tumor types.
Strategic Profile
Pro stress-test →The company is developing SUBA-Itraconazole for late-stage, metastatic castrate-resistant prostate cancer (mCRPC) and late-stage non-squamous non-small cell lung cancer (NSCLC). Inhibitor's business model centers on drug repurposing—licensing approved pharmaceuticals and obtaining patent-protected methods of use and delivery, enabling faster clinical development pathways compared to traditional novel drug discovery. This approach reduces development risk while leveraging well-characterized safety profiles.
Competitive Landscape
Pro stress-test →Inhibitor operates in the oncology and rare disease therapeutics space where it competes indirectly with larger biopharmaceutical companies developing prostate cancer, lung cancer, and rare skin condition treatments. Direct competitors include early-stage biotech firms pursuing itraconazole-based therapies and large pharma companies with established cancer pipelines. The company's competitive advantage lies in its drug-repurposing methodology and exclusive partnerships (e.g., Johns Hopkins University license) rather than in manufacturing scale or commercial infrastructure.
Industry Context
Inhibitor Therapeutics, Inc. operates in Clinical-stage oncology and rare disease therapeutics.
Key facts
Founded: 1992 · Headquarters: Tampa, Florida · Employees: N/A · Revenue: N/A · Market cap: N/A